SHANGHAI – (BUSINESS WIRE) –EpimAb biotherapeutics, a clinical-stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as Chief Technology Officer of EpimAb. Dr. Su joined EpimAb in December 2019 as Senior VP, CMC, and led the completion of EpimAb’s early CMC development facility in Suzhou BioBay. In this newly created position, Dr. Su continues to oversee the company’s CMC design and manufacturing operations.
“Since joining EpimAb, Jerry has made a significant contribution to the organizational growth of EpimAb by successfully closing our fully functional CMC development and manufacturing facility in Suzhou BioBay ahead of schedule, ”said Dr. Chengbin Wu, Founder and CEO of EpimAb Biotherapeutics. “We are very excited to promote Jerry to this new role and look forward to his continued contribution and leadership in advancing the manufacturing strategy as we rapidly advance our pipeline of novel bispecific antibodies. ”
“I am honored to serve in this new role alongside the wonderful team of scientists and industry leaders to scale EpimAb’s efforts to advance bispecific innovation in China and globally, “said Dr. “With three assets in clinical development and several upcoming preclinical programs, efficient R&D and manufacturing operations and regulatory strategies are more important than ever. I look forward to leading our efforts in some of these key areas and harnessing the potential of our bispecific platform technologies to add value for partners and patients. ”
Dr. Su brings over 20 years of engineering and leadership experience in pharmaceutical research and development, manufacturing and CMC to global and Chinese pharmaceutical companies such as Pfizer, Genzyme, Merck and Hengrui and CDMO Wuxi Biologics. Prior to joining EpimAb, he was CEO of Zhejiang Huahai Biopharmaceuticals Co. in Hangzhou. Dr. Su has extensive experience in cell culture, process development, technology transfer, validation, manufacturing and compliance, as well as extensive hands-on experience in filing new drug licenses and providing post-approval product support for regulatory inspection and response preparation and change management. Dr. Su received a Ph.D. in Chemical Engineering with a minor in Statistics from West Virginia University, an MS in Bioprocess Engineering from Beijing University of Chemical Technology, and a BS in Chemical Engineering from Tianjin University.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately held biopharmaceutical research and development company with research and manufacturing facilities in Shanghai and Suzhou, China. Based on a proprietary unique and efficient bispecific antibody technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin), EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focusing on immuno-oncology and other areas of great value to patients are. EpimAb also seeks to diversify its pipeline by selectively licensing its platform and pipeline assets to partners worldwide. For more information, see www.epimab.com